Ticker News
$LABT News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
Life Sciences Virtual Investor Forum presentations now on-demand; LABT among presenters
Presentations from the June 24–25 Life Sciences Virtual Investor Forum are now available on-demand and will be accessible 24/7 for 90 days, with investor download materials and (limited) 1x1 meeting requests noted. Presenting companies include a broad slate of small-cap life sciences and medtech tickers — including LABT, CTSO, PHIO and ATYR — but the release doesn't include new clinical data or company-specific material announcements.
LABT names David G. Armstrong Study Chair for Phase 2a Nu-3 iDFU trial
Lakewood-Amedex (LABT) appointed David G. Armstrong, a leading diabetic foot clinician, as Study Chair and Scientific Advisor for its Phase 2a proof-of-concept trial of topical Nu-3 in infected diabetic foot ulcers. The study will evaluate safety and efficacy of three topical concentrations (2%, 5%, 10%) to support a potential Phase 2b; no clinical data or timelines were disclosed and efficacy/safety remain unproven.
LABT names David Armstrong as Study Chair for Phase 2a Nu-3 iDFU trial
Lakewood-Amedex (NASDAQ: LABT) appointed David G. Armstrong, a globally recognized diabetic foot expert, as Study Chair and Scientific Advisor for its Phase 2a proof-of-concept trial of topical Nu-3 gel in infected diabetic foot ulcers. The Phase 2a will evaluate safety and efficacy of three topical concentrations (2%, 5% and 10%) to support a larger Phase 2b, and Armstrong's involvement could strengthen trial design, enrollment and clinical credibility. The company did not report clinical data or timing — this is a leadership/operational milestone rather than a readout.
HPW Investments reports 24.04% stake in Lakewood-Amedex (Schedule 13G)
ISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC. filed SEC Form SCHEDULE 13G. HPW Investments Holding Ltd. reported beneficial ownership of 3,435,501 common shares of Lakewood-Amedex Biotherapeutics (LABT), equal to 24.04% of 14,290,892 shares outstanding as of March 31, 2026, in a Schedule 13G filed 06/23/2026. The filer states it has sole voting and sole dispositive power over all 3,435,501 shares and lists its principal business office in Jersey.
Life Sciences Virtual Investor Forum set for June 24-25; multiple biotech/medtech tickers to present
Virtual Investor Conferences published the agenda for its Life Sciences Virtual Investor Forum on June 24-25, listing live presentations from roughly 30 life sciences companies (see tickers below). Participation is free, investors can watch live presentations and schedule one-on-ones; Lakewood‑Amedex (NASDAQ: LABT) is slated to present June 25 at 11:00 AM ET.
Lakewood-Amedex (LABT) wins Australia composition-of-matter patent for Bisphosphocin antimicrobials
Lakewood-Amedex (LABT) said IP Australia issued a composition-of-matter patent (issued March 5, 2026) protecting its Bisphosphocin® class of fast-acting, broad-spectrum antimicrobial compounds being developed for complicated urinary tract and pulmonary infections. The company says the grant enlarges its global IP footprint (now citing 72 granted and 29 pending patents), which could bolster exclusivity and licensing leverage, but no new clinical data or regulatory milestones were announced and the patent alone does not reduce development or commercialization risk.
LABT to Present June 25 on Nu-3, Plans for Phase 2 in Infected Diabetic Foot Ulcers
Lakewood-Amedex (NASDAQ: LABT) said CEO Kelvin Cooper will present at the Life Sciences Virtual Investor Forum on June 25 to outline the company's growth strategy and its lead candidate Nu-3, a topical gel being developed for infected diabetic foot ulcers (iDFU). The company said it intends to advance Nu-3 into Phase 2 trials and highlighted its Bisphosphocin® platform as a fast-acting, broad‑spectrum antimicrobial that targets resistant pathogens (e.g., MRSA, VRE); the release contains no new trial data and timing remains forward-looking.
LABT: Nu-3 gel patents granted in Australia & New Zealand; global IP now ~71 granted/28 pending
Lakewood-Amedex (LABT) announced two new patents granted in Australia and New Zealand covering the gel formulation of its lead antimicrobial Nu-3, expanding protection for the topical product. The company says its global Bisphosphocin patent estate now totals about 71 granted and 28 pending applications (~99 total) covering composition, formulation and use; the Nu-3 gel is being advanced into Phase 2 for mildly infected diabetic foot ulcers. Lakewood-Amedex plans an initial Phase 2a safety/dose-response study followed by a placebo-controlled Phase 2b to determine dosing and regimen.